2013-08-21 07:33:01 -
Medigene AG /
Medigene to implement 4:1 share capital reduction effective 3 September 2013
. Ad hoc announcement according to § 15 WpHG. Processed and transmitted by Thomson Reuters
The issuer is solely responsible for the content of this announcement.
* Number of shares issued decreases from 39.5 million to 9.9 million by
consolidation of the shares at a ratio of 4:1
* Conversion of shares to take place on September 3, 2013
Martinsried/Munich, 21 August 2013. Medigene AG (MDG, Frankfurt, Prime Standard)
announces that the 4:1 share capital reduction approved at the annual general
meeting on 16 July 2013 will be executed as planned following its recent entry
into the Commercial Register. Using
a consolidation ratio of 4:1 the number of
shares issued decreases from 39,488,556 to 9,872,139. The conversion of the
shares in the share deposit accounts will take place automatically with a value
date of 3 September 2013. This measure has no impact on the individual
shareholders' percentage share in Medigene AG. Starting 3 September 2013, the
converted Medigene shares will be traded with the new security identification
number WKN A1X 3W0 (ISIN: DE000A1X3W00).
By consolidation of the shares, Medigene's share capital is reduced by
EUR 29,616,417.00 to EUR 9,872,139.00 for 9,872,139 shares outstanding. The
difference of EUR 29,616,417.00 will be transferred from subscribed capital to
capital reserves on the liabilities and shareholders' equity side, leaving the
sum of shareholders' equity and the balance sheet of Medigene AG unchanged.
For those shareholders whose share participation cannot be divided by 4 at
closing on the reference date 2 September 2013, individual shareholders will be
offered the opportunity to buy or sell 0.25 to 0.75 portions of Medigene shares
to achieve a whole share. Shareholders will receive a letter to this effect from
their depository bank after 3 September, 2013. If a shareholder does not give
any instruction to the depository bank for this adjustment the fractional
portion of shares will be sold and the proceeds will be credited to the
Medigene AG (Frankfurt: MDG, Prime Standard) is a publicly listed biotech
company headquartered in Martinsried/Munich, Germany. Medigene focuses on
clinical research and development of novel drugs against cancer and autoimmune
diseases. Medigene is the first German biotech company to generate revenues from
a marketed product (Veregen(®)), which is distributed by partner companies.
Medigene also has two drug candidates undergoing clinical trials, EndoTAG(®)-1
und RhuDex(®), and is developing an innovative vaccine technology. For further
details, please visit www.medigene.com
This press release contains forward-looking statements representing the opinion
of Medigene as of the date of this release. The actual results achieved by
Medigene may differ significantly from the forward-looking statements made
herein. Medigene is not bound to update any of these forward-looking statements.
Medigene(®) is a registered trademarks of Medigene AG. This trademark may be
owned or licensed in select locations only.
Julia Hofmann, Claudia Burmester
Investor & Public Relations
Tel.: +49 - 89 - 20 00 33 - 33 01
To unsubscribe from the press release distribution list, please go to
Press release as PDF:
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Medigene AG via Thomson Reuters ONE